American pharmacist, Union Army officer, businessman, philanthropist
In this episode of Let Go & Lead, Innovisor Founder and CEO Jeppe Hansgaard talks with Maril about how influence really works within organizations. Diving into the field of Organizational Network Analysis (ONA), they discuss the enormous impact that a few employees have on the success of their entire organizations — Innovisor has shown that just 3 percent of your employees can impact up to 90 percent of change — and how rarely leaders can guess who those people really are within their own ranks. Jeppe and Maril explore the different ways that networks change as you progress up organizations; how Gagen's Six Levers of Culture can go hand-in-hand with ONA; and the promise of network analysis as a boon for human connection, belonging and organizational agility. Learn about: 5:23 How 3% of your employees impact 90% of change 9:54 How COVID-19 has changed organizational networks 11:23 Understanding gender in informal networks 14:39 How Gagen's Six Levers of Culture connect to organizational network analysis 20:05 Assisting the “Lost Generation” inside your organization 25:27 The impact of Organizational Network Analysis on Mergers & Acquisitions 33:06 The most influential person in the organization — Jeppe Vilstrup Hansgaard is the Founder and CEO of Innovisor, a boutique advisory within organizational network analysis and change analytics that has a bold vision to eliminate change failure. Jeppe has working experience from across five continents, including from many U.S. companies such as Chevron, Caterpillar and Eli Lilly. He is a frequent speaker to executive groups, leadership programs and business schools around the world. His and Innovisor' s groundbreaking work has been featured in more than 15 leadership books, including Lean In by Sheryl Sandberg. Jeppe holds an Executive MBA from Henley Business School, U.K., and a Certificate in Strategic Decision and Risk Management from the Stanford Center for Professional Development. Jeppe is the proud dad of three kids, and spends most of his spare time helping out in the local track & field community. — Let Go & Lead is a leadership community created by Maril MacDonald, founder and CEO of Gagen MacDonald. Maril brings together provocateurs, pioneers, thought leaders and those leading the conversation around culture, transformation and change. Over the course of the past 12 years, Let Go & Lead has existed in many forms, from video interviews to resource guides to its current iteration as a podcast. At its core, it remains a place where people can access a diversity of perspectives on interdisciplinary approaches to leadership. Maril is also working on a book incorporating these insights gathered over the past several years from global leaders and change makers. Maril has interviewed over 120 leaders — from business to academia and nonprofits to the arts — through the years. In each conversation, from personal anecdotes to ground-breaking scientific analysis, she has probed the lessons learned in leadership. From these conversations, the Let Go & Lead framework has emerged. It is both a personal and organizational resource that aims to serve the individual leader or leadership at scale. Full episodes also available on: Apple Podcasts: https://podcasts.apple.com/us/podcast/let-go-lead-with-maril-macdonald/id1454869525 Spotify: https://open.spotify.com/show/5Gaf7JXOckZMtkpsMtnjAj?si=WZjZkvfLTX2T4eaeB1PO2A Google Podcasts: https://podcasts.google.com/feed/aHR0cHM6Ly9sZXRnb2xlYWQubGlic3luLmNvbS9yc3M Stitcher: https://www.stitcher.com/show/let-go-lead — Gagen MacDonald is a strategy execution consulting firm that specializes in employee engagement, culture change and leadership development. Learn more at http://www.gagenmacdonald.com.
Die Stimmung an den Aktienmärkten kann sich ganz schnell drehen. So auch gestern, der DAX schaffte nach schwachem Start die Kehrtwende und schloss im Plus. Heute kann er auf positive Vorgaben von den US-amerikanischen und asiatischen Börsen bauen.
Justin Nielsen and Irusha Peiris discuss how to avoid getting chopped up in a prolonged bear market. When a bear market persists, preservation of capital becomes even more important. We also get a surprise visit from hedge fund manager Jim Roppel. He discusses the opportunities that come after bear markets and current stocks showing leadership qualities including Biogen (BIIB), Eli Lilly (LLY), Aspen Tech (AZPN), Enphase (ENPH), and ShockWave (SWAV). For the video version, visit investors.com/podcast.
In der heutigen Folge „Alles auf Aktien“ sprechen die Finanzjournalisten Anja Ettel und Holger Zschäpitz über die britische Notenbank als Kavallerie der Märkte, die Gaspreisdeckel-Klatsche für Energiefresser und frischen Wind fürs Depot. Außerdem geht es um Porsche, Biogen, Eisai, Roche, Morphosys, Eli Lilly, ThyssenKrupp, Salzgitter, Commerzbank, Deutsche Bank, Apple, VW, Glencore, Ginkgo Bioworks, Invitae, Twist, 10x Genomics, Uipath, Invesco Wind Energy (WKN: A3DP7S), Global X Wind Energy (WKN: A3C9MA), Orsted, Siemens Gamesa, Vestas, Boralex, Axiona Energias Renovables, Ming Yang Smart Energy, SGL Carbon, SKF, Encavis, Energiekontor und Brookfield Renwable. Wir freuen uns an Feedback über firstname.lastname@example.org. Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html
Der Dow Jones büßte gestern seine anfänglichen Gewinne schnell wieder ein. Am Ende des Handelstages schloss er mit einem Minus von 0,4 Prozent. Zumindest dem Nasdaq 100 gelang es leicht um 0,16 Prozent zuzulegen.
The SURPASS program of phase 3 clinical trials led to the 2022 FDA approval and positive CHMP opinion of the first GIP/GLP-1 receptor agonist, tirzepatide. Join Prof Carol Wysham for an examination of the clinical data from these trials and their potential impact on type 2 diabetes management. By completing this activity, you can qualify for 0.25 CME credits. To claim your credits, you must listen to the podcast and successfully pass the post-module assessment at https://diabetes.knowledgeintopractice.com, where you can find all past episodes of the podcast as well as other free CME resources. Learning objective After listening to this podcast series, learners will be able torecall the results of recent clinical trials for GIP/GLP-1 dual agonists References available here Disclosures Prof. Carol Wysham declares the following financial relationships from the past 24 months: Research Funding: Novo Nordisk; Eli Lilly Liberum IME staff, ACHL staff, and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose. The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity. The content for this series was developed independently of the ineligible companies. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantors. This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis. This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers' prescribing information for these products. ACHL requires its speakers to disclose that a product is not labeled for the use under discussion. Funding: This independent educational activity is supported by an educational grant from Eli Lilly. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Eli Lilly has had no influence on the content of this education.
Dr Joseph Antoun, physician and CEO of L-Nutra has a passion to bring fasting to the world and help humanity to live in a more healthy way and longer He talks with Angela about his research and how the fast mimicking diet means you can move to autophagy and protect your lean muscle Understand more about how to optimise fasting and longevity in this informative episode KEY TAKEAWAYS There are 2 categories of fasting – intermittent and periodic Autophagy begins for most people at around 48 hours and the most important aspect of fasting is stressing the body Stress elevates cortisol and with a focus on protein you can restructure muscle The duality of fasting means you are accessing your fat reserve and protecting lean muscle mass Fasting allows you to go beyond day 2 and Prolon's five-day regime effectively supports this A cellular fast means the cells are getting nutrients but not spiking insulin The body switches to keto and autophagy on days 2 and 3 and then on days 4 and 5 the feeling is euphoric and cells are being rejuvenated The mimicking fasting diet puts the body in a good metabolic state to optimise nutrition around your treatment Intermittent fasting can help to keep cancer cells in check in the early stages Cancer cells can't survive fasting mode because they need calories, they don't know how to stop replicating by design BEST MOMENTS ‘It's not sci-fi it's the speed of the crisis, the intensity of the crisis and how much reserves you have to compensate for it' ‘If you want to benefit from autophagy you have to give it time' ‘Prolon is short enough that people can do it but long enough to get people into autophagy' You should be aiming to under nourish cancer cells not feeding them to grow RESOURCES FOR THIS EPISODE https://www.linkedin.com/in/drjosephantoun https://mobile.twitter.com/drjosephantoun https://prolon.co.uk/ https://l-nutra.com/ VALUABLE RESOURCES High-Performance Health Podcast Series -https://angelafosterperformance.com/podcasts/ Biohack Your Way to Your Best Self - Join My Exclusive Female Biohacker Collective – angelafosteracademy.com/female-biohacker-collective-enrol Get a free health check and personalised report www.yourtotalhealthcheck.com Watch my Free Masterclass on how to master your metabolism -www.angelafosteracademy.com/master-your-metabolism Download my free Guide to Harmonising Your Hormones -www.angelafosterperformance.com/hormones Download my free Fasting Guide - www.angelafosterperformance.com/fasting/ Download my free Guide to Sleep Like a Boss -www.angelafosterperformance.com/sleep Join my free Facebook Community -www.facebook.com/groups/femalebiohacker Get my bestselling book Rethink Health - https://amzn.to/3vbzYOV ABOUT THE GUEST Dr. Joseph Antoun always knew he wanted to help others through medicine, which is why he trained to be a physician. Eventually, he figured out that medicine was actually sick care, treating patients after their health had already declined. Dr. Antoun wanted to be at the forefront of changing our current healthcare system of sick care to a more proactive approach, which meant taking care of our existing good health. After years of working at pharmaceutical companies and, later, focusing on public health policy, he found what he was searching for at L-Nutra, Inc., a cutting-edge nutri-technology company. Dr. Joseph Antoun is CEO & Chairman of the Board of L-Nutra and Member of the Forbes Business Development Council. He's the former CEO of Health Systems Reform, a boutique consultancy aimed at improving public health by reforming health systems, management, and delivery. Prior to that, he was Director of Health Policy at the University of Chicago, Editor in Chief of the Journal of Health Systems and Reform and head of Business Development for Eli Lilly & Co. He completed his studies in Public Policy at Harvard University, in Public Health at Johns Hopkins University, and his Doctorate in Medicine and Masters' in Medical and Biological Sciences at Saint Joseph University. CONTACT DETAILS https://www.linkedin.com/in/drjosephantoun https://mobile.twitter.com/drjosephantoun ABOUT THE HOST Angela Foster Angela is a Nutritionist, Health, and Performance Coach. She is also the Founder and CEO of My DNA Edge, an Exclusive Private Membership Site giving individuals the tools and bio hacks needed to optimise their genetic expression for optimal health and performance. After recovering from a serious illness in 2014, Angela left the world of Corporate Law with a single mission in mind: To inspire and educate others to live an energetic, healthful, and limitless life. Angela believes that we can truly have it all and has spent the last 5 years researching the habits and routines of high performers, uncovering age-old secrets, time-honoured holistic practices, and modern science to create a blueprint for Optimal Human Performance. CONTACT DETAILS Instagram Facebook LinkedIn See omnystudio.com/listener for privacy information.
Epidemiologist Dr. David Egilman of Brown University joins Dash to discuss his experience testifying as an expert witness in over 600 cases against some of the world's largest corporations, including Johnson & Johnson, Eli Lilly, and Merck. Dr. Egilman's testimonies have recovered billions of dollars worth of settlements for injured/sick workers and consumers. Dr. Egilman explains the ethical implications of corporations funding their own science and research. He also shares effective ways that society can take its power and health back from the grips of industry giants. Dr. David Egilman is board-certified in internal medicine and preventive and occupational medicine and an epidemiologist. He's also the previous Editor in Chief of the International Journal of Occupational and Environmental Health and the current Editor of the The Journal of Scientific Practice and Integrity.
In this episode we welcome Stacy Johns, Chief Financial Officer for the Los Angeles Football Club of MLS. Stacy shares her incredible career journey where she built her foundation in Finance with Ernst & Young and Eli Lilly. Thanks to her hard work, relationship building, and never passing up an opportunity, she was swept away from the public sector and into the sports industry where she worked for the the Indianapolis Colts for 16 seasons before being named as the CFO for LAFC.
In today's episode, we welcome expert Oncologist Dr. Lori Wirth and expert Pathologist Dr. Thomas Giordano to discuss the challenges they have encountered and strategies that they have implemented to improve multidisciplinary collaboration in the management of patients with thyroid cancer and continued integration of precision medicine approaches. References Kilagat K, Griffin MJ, Baik F, et al. Thyroid Care Collaborative: an electronic health record facilitating multidisciplinary management of thyroid cancer. Int J Endo Oncol 2018;5(1):IJE03 Target Audience: Oncologists, pathologists and other HCPs involved in the diagnosis of RET and TRK cancers, with a focus on community practitioners. Learning Objective: Recall thyroid RET and TRK fusion-positive cancer diagnosis and relevant genomic testing guidelines and identify ways to adapt the guidelines to local settings Discuss “precision medicine” and new technologies, including “liquid biopsy” Review the organisation of care and strategies for more efficient care delivery These learning objectives are for the podcast series. This episode focuses on the third objective. By completing this module you can qualify for 0.25 CME credits. To claim your credits, you must listen to the podcast and successfully pass the post-module assessment. Funding Information: This episode is supported by an educational grant from Eli Lilly, who have had no influence on the content or choice of faculty. Staff Disclosures: Dr Lori Wirth Advisory Board - Bayer Healthcare, Coherus, Eli Lilly, Eisai, Exelixis, PDS Biotechnology Corp Consultant - Curie Therapeutics, Morphic Therapeutics Dr. Thomas Giordano No relevant disclosures to declare
Die Wall Street hat bisher eine schwierige Woche hinter sich. Und es sieht nicht danach aus, als ob heute noch Besserung eintreten könnte. Vorbörslich sind die großen Indizes allesamt deutlich unter Druck.
Tag Eins nach der Fed-Sitzung. Gestern waren die großen US-Indizes nach Verkündung der Fed-Maßnahmen mit einem deutlichen Minus aus dem Handel gegangen. Heute scheint die Wall Street vorbörslich zunächst auf Richtungssuche.
Another volatile day on Wall Street as investors fear the Federal Reserve's rate hikes could push the economy into recession. Fairlead's Katie Stockton says the market has long-term downward momentum and investors should be skeptical of any bounces right now. But CFRA's Sam Stovall says October is typically a bottoming month for the market and thinks we could be setting up for an end of year relief rally. Wells Fargo's Mike Mayo on what the latest Fed rate hike means for the banks and which financial stocks he thinks are the most attractive. UBS' Colin Bristow upgrading shares of Eli Lilly and explains why its new weight loss drug could be the "biggest drug ever". And Mizuho's Dan Dolev downgrading Block and says corporate mismanagement is blocking growth.
John M. O'Brien, President and CEO of the National Pharmaceutical Council (NPC), joins us for episode 27 of the IPhO Podcast! John has quite the resume, having worked in pharma, academia, health policy, and government—just to name a few—throughout his career. Growing up, he wanted to be a sports broadcaster. But watching how much of an impact medicine made on his own mother's life changed his career plans entirely. Since then, he's gone on to establish himself as a leader in Healthcare Policy, influencing decisions that have positively impacted access to medications for millions of patients. We can't wait for you to listen and meet John, learn a bit about the NPC Fellowship Program, and gain a better understanding of what it means to work in this important realm of industry. A special thank you to our episode sponsors, Eli Lilly and Company, UCB, and UNC Eshelman School of Pharmacy! Eli Lilly and Company: https://www.industrypharmacist.org/resources/70f55464042425ad7ff4d0442279d7fc.pdf UCB: https://www.industrypharmacist.org/resources/3880d166c5aba7c0772ffb6966a64e7b.pdf UNC: https://pharmacy.unc.edu/education/fellowships/
Gastrointestinal cancer experts Dr. Aparna Parikh and Dr. Kristin Ciombor discuss the treatment implications of the phase 3 PARADIGM trial and other advances in colorectal cancer with guest host and ASCO Daily News Associate Editor, Dr. Shaalan Beg. TRANSCRIPT Dr. Shaalan Beg: Hello, and welcome to the ASCO Daily News Podcast. I'm Dr. Shaalan Beg, your guest host of the ASCO Daily News Podcast today. I'm an adjunct associate professor at UT Southwestern's Simmons Comprehensive Center and vice president of Oncology at Science 37. I'm delighted to welcome Dr. Aparna Parikh, and Dr. Kristen Ciombor to the podcast today. Dr. Parikh is an assistant professor of Medicine at Harvard University and a GI medical oncologist at the Mass General Hospital Cancer Center. Dr. Ciombor is an associate professor of Medicine and GI medical oncologist at the Vanderbilt University Medical Center. Today, we'll be discussing exciting new approaches using EGFR inhibitors as frontline therapy in colorectal cancer, and promising advances with immune therapy in the treatment of rectal cancer. Our full disclosures are available in the show notes, and disclosures of all guests on the podcast can be found in our transcripts at: asco.org/podcasts. Dr. Parikh, and Dr. Ciombor, it's great to have you on the podcast today. Dr. Aparna Parikh: Thanks so much. Dr. Kristen Ciombor: Thanks so much for having us. Dr. Shaalan Beg: We've seen some exciting advances in GI oncology this year. Let's start with colorectal cancer. Dr. Parikh, there have been many trials looking to compare EGFR and VEGF inhibitors in colorectal cancer. We've heard about the IDEA studies, the FIRE trials, and CALGB 80405. At the 2022 ASCO Annual Meeting, we heard the results of the PARADIGM trial. Have we finally answered the question of when to use EGFR inhibitors as frontline therapy for colorectal cancer? Dr. Aparna Parikh: Thanks so much, Dr. Beg, for this great question. It has been a really exciting year for colorectal cancer across the board. So, the anti-EGFR story is really interesting and has evolved. And maybe just for a little bit of background, we know that colorectal cancer originating from both the right and left side of the colon differ. So, they differ embryologically, and epidemiologically; there are different genetic and molecular aspects to right and left sides of colon cancers. And we have learned over time that in the era of targeted therapy, the primary tumor location has been found to play a very important role, not only in the prognosis of patients but to predict treatment response. We know that patients that have left-sided colon cancers-- and when we think about left-sided colon cancers, we think about cancers that originate from the splenic flexure and descending colon, sigmoid colon, rectosigmoid junction, and sometimes include the rectum in this as well. The rectals have slightly different molecular features than distal colons. And we know that these left-sided patients, overall, have better survival benefits than patients that have right-sided CRC. And that includes again, cecum, ascending colon, hepatic flexure, and transverse colon. So, we know that that had prognostic implications, but what about the predictive implications? And with ASCO, we saw some really exciting data with the PARADIGM study, as Dr. Beg highlighted. We have seen many examples in the past showing the predictive power of anti-EGFR therapy, and anti-EGFR therapy showing a detriment for patients on the right side of the colon. But all these results historically have been obtained by retrospective analysis. So, retrospective analysis of the pivotal CALGB 80405 study, which is the first-line biologic trial. FIRE-3, which is a similar study, but done out of Europe, and KRYSTAL. So all these studies show the same finding but were all obtained basically by retrospective analysis. And what we saw with PARADIGM this year, which is exciting to see, is that this was the first prospective trial to test the superiority of an anti-EGFR inhibitor panitumumab versus bevacizumab in combination with standard doublet first-line chemotherapy for patients that were RAS-wild type. I guess I forgot to mention that again, anti-EGFR therapies are only eligible for patients that are RAS-wild type. We know that RAS-mutant patients and RAS, KRAS HRAS patients don't respond to anti-EGFR therapy. So, the study was looking at RAS-wild type patients, and again, asking the question “was panitumumab better than bevacizumab in combination with chemotherapy for these RAS-wild type patients and for left-sided tumors?” It was a multicenter trial done in Japan-- and I always commend the Japanese on their work and their designs and ability to do these studies that ask really important questions. And, overall survival was the primary endpoint of the study in patients with left-sided tumors, but they also did a full set analysis including patients that didn't have left-sided tumors. They had 823 randomized patients. Many patients, a handful did not receive per-protocol treatment, and some were excluded for other reasons relating to inclusion criteria. And they had 400 patients that ultimately received panitumumab and 402 patients that received bevacizumab in the full set analysis. And of those patients, there were 312 and 292 respectively had left-sided tumors. And although the PFS was comparable between the treatment group, we saw that panitumumab in the left-sided patients actually did improve the OS in both patient populations. But when you looked at the left-sided tumors, the difference was 37.9 versus 34.3 months meeting statistical significance. So, this was an exciting study because it confirmed prospectively what we have seen time and time again, and really behooves us to do early biomarker testing and know RAS status early for these patients with right-sided tumors, as they do derive benefit from anti-EGFR. Maybe I'll just pause there and open it up for more questions or comments from Dr. Ciombor as well. Dr. Kristen Ciombor: Yeah, Dr. Parikh, I thought these data were encouraging. And as you mentioned, the first prospective data that we have in this setting now that we know this primary tumor sidedness matters. Just on a practical note, what do you do in practice? Do you give a lot of anti-EGFR in the first-line? I find that the toxicity can be challenging sometimes and patients may not want to do that. So, it leaves us in a quandary sometimes. Dr. Aparna Parikh: Yeah. So, what's interesting and I don't think we have this data clearly answered yet is, I had, especially for kind of a fit patient-- with the previous data that we've seen with TRIBE and others showing a survival benefit with triplet chemotherapy for first-line therapy, my inclination had actually been to prefer triplet-- and we know that triplet and anti-EGFR toxicity-wise is really, really tough to manage, and really no benefit there that we've seen with OS or PFS, even though you maybe do get a little bit of a better response rate with that. And so where I have sort of struggled is triplet versus just doing first-line doublet plus anti-EGFR. You know, we are not having a discussion about triplet today, but we also saw some data at ASCO showing that perhaps the benefit of the triplet, with the triplet study, is not as much as we had hoped it would've been too. So, it's a good question. I do tend to prefer triplet, I guess, overall, for the healthy, good performance status patient. And then, if not, then doublet. And we, unfortunately, don't have kind of rapid EGFR testing, we're pushing for that. In practice, I think having RAS/RAF status up front would be entirely helpful. It's lumped into our pan-tumor profiling, comprehensive genomic panels. We get microsatellite instability (MSI) status, which I know we'll talk about here next right away. But I think another reason that oftentimes we don't add it right away, is because we don't have the RAS status right away. So, you just start with a doublet and you may end up sneaking it on later. And then, I'd love to, maybe in another podcast, where we can discuss second-line anti-EGFR therapies and what people do in practice for those right-sided patients should they never get anti-EGFR and later-lines of therapy too. And I would argue, perhaps not, because we do see some patients that do benefit, but it can be challenging sometimes with a fresh new patient to make these decisions. But at least, feel encouraged that we're doing the right thing by adding anti-EGFR therapy if they can tolerate it for the left-sided RAS-wild type patient. How about you? What do you do? Dr. Kristen Ciombor: Yeah. Largely, it's a great question. And I don't love giving anti-EGFR therapy. We have an additional issue where I am geographically in that we don't ever give cetuximab because of the high rates of an infusion reaction. So, we pretty much stick to panitumumab and are glad to have that option. But I have started to talk to patients about toxicity and I'm really upfront with the survival data. And it's interesting how people choose differently in terms of what's important to them. And whereas a few extra months in the overall survival may be overshadowed by the toxicity that they have to go through to accomplish that. So, it's good to have many options though, and that's the important thing, and I think the takeaway, as well. Dr. Shaalan Beg: So, kind of brings it back to the fundamentals of practicing medicine, right? Bringing our patients and giving them the options that are most available to them. But I'm going to ask both of you one by one: So, if we have our patient with left-sided colorectal cancer, known as KRAS RAS-wild type, do you recommend EGFR therapy and VEGF therapy and allow the patients to decide, or do you feel that we decide if their profile is such that we should continue with VEGF therapy instead? Dr. Ciombor, do you want to go first? Dr. Kristen Ciombor: Yeah, I think both are good options. I don't only do bevacizumab in the first-line by any means because we do have that survival data. It mostly comes down to a discussion with the patient in terms of toxicities and survival and how well those balance out. Dr. Aparna Parikh: Yeah, very similar. I think we have also gotten a little bit more adept at managing toxicity. I'm pretty aggressive about prophylaxis with even doxy and topicals for managing the rash. And so, for some of my younger patients who are wanting to be "aggressive" and want the exposure to anti-EGFR early but are still very mindful of how it's impacting their day-to-day semblance of self, especially for the younger patients, try to be very proactive about side effect management. And then, of course, we have the patients that have the electrolyte wasting and things too that sometimes if it's bad, we are stuck with infusions frequently and you may end up dropping for those patients. But I think the rash at least I feel like for most patients we can manage if you're aggressive about it too. And I think we have gotten better at that than we were many years ago. Dr. Kristen Ciombor: Never thought we'd be dermatologists, did we? In training, that was definitely not a path I was good at. Dr. Shaalan Beg: Dermato-Oncology, rapidly growing field. So, Dr. Ciombor, the rectal cancer space has evolved very rapidly in recent years, especially when we hear about total neoadjuvant therapy, short-course radiation, watch-and-wait, for those with complete clinical responses. So at ASCO this year, we heard results on immune therapy and rectal cancer. Can you summarize where we are with immune therapy and rectal cancer? Dr. Kristen Ciombor: So, yes. We heard a lot this year at ASCO; both at ASCO GI and ASCO, from the Memorial group and Dr. Cercek's group. And this has been a really exciting advance that we're starting to see and potentially paradigm-shifting data. So, we know-- as you mentioned, that our treatment of rectal cancer, specifically, locally advanced rectal cancer has changed a lot in the last few years with a shift to more Total Neoadjuvant Therapy. And what the Memorial data showed was that for the patients who have microsatellite instability or mismatch repair deficiency, which admittedly, is a small group, but certainly ones that we see in clinic, those patients, on their trial were treated with six months of dostarlimab as neoadjuvant therapy prior to any other treatment; before radiation, surgery, et cetera, and no chemotherapy. And what they found was that actually, six months of dostarlimab in the first 14 evaluable patients actually induced a 100% clinical complete response rate. So, it's really unheard of in most of our trials to see 100%. And I think that caught everyone's attention for sure. I think we have to keep in mind who these patients were and are because they are currently being followed. So, for instance, these were patients that had pretty bulky node-positive disease, almost all these patients did. These were not really early-stage tumors. We did see that 100% were BRAF-wild type, so it does tell us maybe this is not completely the population that we're all seeing when we do see microsatellite instability since we see a lot of sporadic tumors with BRAF mutations. But on the whole, I mean, these were all MSI-high patients and treated with dostarlimab; the six months, that was the total amount of treatment that they received, though a few patients achieved that clinical complete response earlier at about three months, at the three-month reassessment. And what the clinical complete response rate was, was looking both radiographically, as well as endoscopically, and not seeing any sign of residual tumor. I think the important thing here is that median follow-up is still pretty short. There are a few patients who are approaching now two years past that dostarlimab therapy and have not had tumor recurrence, but overall, the median follow-up is still quite short. So, I think we do need to continue to follow these patients. We don't have overall survival data yet either. I think we still have a lot to learn, but this is a very encouraging start and certainly, something that could be really treatment-changing for these patients, which again, as Dr. Parikh was saying, we need this molecular profiling early to make treatment decisions right off the bat, not even only for metastatic now, but even for these locally-advanced rectal cancer patients. Because if you think about it, we've all taken care of patients who have to go through chemoradiation, and chemo, and surgery, and have a lot of morbidity from those treatments so that even if you cure them, they're left with a lot of toxicity. So, if we could avoid some of that, even potentially, surgery, that would be wonderful. But I do caution that this is not the standard of care yet. This is only based on 14 patients with short follow-ups at the current time. But the trial is ongoing, and there are other trials open in this space for patients who don't live in New York or can't get to New York. And for instance, ECOG-ACRIN study 2201 is treating these same patients with nivo and ipi, as opposed to dostarlimab. And that trial is open in about 80 sites now across the US. So hopefully, geographically near all of these patients. Dr. Shaalan Beg: I think a lot of us and a lot of our listeners, that Monday after the results were announced on ASCO had our phone lines and our patient secure messaging lines blowing up. Dr. Kristen Ciombor: We should have warned our nurses and our treatment teams that they would be fielding these questions, yes. On one hand, it's wonderful that our data and the science is getting out to patients. But I think we also have to be really careful as to what is reaching them because many of them didn't realize it was for this subset of patient populations. But great that they're asking those questions and wondering-- being advocates for themselves too. Dr. Shaalan Beg: You use the term clinical complete response. Can you talk about how we determine someone has a complete clinical response and what their follow-up looks like? Dr. Kristen Ciombor: Yeah. In the context of this study, it was actually, as I mentioned, it was both radiographic complete response, as well as endoscopic. So that's one thing that is a little bit tricky when you think about surveillance of these patients. So, it requires a lot, both in frequent surveillance, MRIs, FLEX SIGs often, digital rectal exams, sometimes doing PET scans or CTs, and patients who-- not only on this kind of study but also in non-operative management; watch-and-wait - really have to commit to very close, very frequent follow-up because if the cancer recurs, we don't want to miss that and lose our chance to cure them. So I think that's a little bit different everywhere, how that watch-and-wait approach really manifests, but I think we're learning how to do that, and working in a multidisciplinary group to make sure that patients get the surveillance that they need. Dr. Aparna Parikh: Yeah. I totally agree. If we offer, for the MSI-high patients, if we ultimately end up offering neoadjuvant immunotherapy-- and actually, I'm looking forward to your study, Dr. Ciombor, too, I think the monotherapy versus doublet, too, is going to come up for these patients. But I had a patient just a week or two ago that was starting on this approach with neoadjuvant immunotherapy, but for now, as a group, if we're proceeding down that and they do get a clinical complete response, we're deciding to forego even the radiation and surgery. We're following what they did in the OPRA study, which was pretty aggressive surveillance on the backend, both with direct visualization and MRIs, and you're seeing these patients every three months or so. Dr. Shaalan Beg: Well, thank you Dr. Ciombor and Dr. Parikh for sharing some valuable insights with us on the podcast today. Dr. Aparna Parikh: Thanks so much for having us. It was a lot of fun. Dr. Kristen Ciombor: Thanks for having us on. Dr. Shaalan Beg: And thank you to our listeners for your time today. If you value the insights that you hear on the ASCO Daily News podcast, please take a moment to rate, review and subscribe, wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers: Dr. Kristen Ciombor @KristenCiombor Dr. Aparna Parikh @aparna1024 Dr. Shaalan Beg @ShaalanBeg Listen to additional episodes on advances in GI oncology: Novel Therapies in GI Oncology at ASCO22 ASCO22: Key Posters on Advances in GI Oncology Follow ASCO on social media: @ASCO on Twitter ASCO on Facebook ASCO on LinkedIn Disclosures: Dr. Shaalan Beg: Employment: Science 37 Consulting or Advisory Role: Ipsen, Array BioPharma, AstraZeneca/MedImmune, Cancer Commons, Legend Biotech, Foundation Medicine Research Funding (Inst.): Bristol-Myers Squibb, AstraZeneca/MedImmune, Merck Serono, Five Prime Therapeutics, MedImmune, Genentech, Immunesensor, Tolero Pharmaceuticals Dr. Kristen Ciombor: Consulting or Advisory Role: Merck, Pfizer, Lilly, Seagen, Replimune, Personalis Research Funding (Inst.): Pfizer, Boston Biomedical, MedImmune, Onyx, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Merck, Novartis, Incyte, Amgen, Sanofi Recipient, Bristol-Myers Squibb, Array BioPharma, Incyte, Daiichi Sankyo, Nucana, Abbvie, Merck, Pfizer/Calithera, Genentech, Seagen Travel, Accommodations, Expenses Company: Array Dr. Aparna Parikh: Stock and Ownership Interests: C2i genomics Consulting or Advisory Role: Eli Lilly, Natera, Checkmate Pharmaceuticals, Pfizer, Roche/Genentech, Inivata, Biofidelity, Guardant Health Research Funding(Inst.): PMV Pharma, Plexxikon, Bristol-Myers Squibb, Genentech, Guardant Health, Array, Eli Lilly, Novartis Pharmaceuticals UK Ltd., PureTech, Mirati Therapeutics, Daiichi Sankyo
Ever overthink things and hesitate to find your leadership voice? Stop being in the background and start evolving your own unique perspective so that you can become a great leader. Find inspiration from those you admire and successful companies driving the way to the next big thing. Every successful leader has their own distinct style. I host Nelson Freitas, CSO of Omnicom, where he shares his experience of becoming a successful leader by finding the courage to develop his own style and finding inspiration from unique sources. Nelson Freitas is Global Chief Strategy Officer at Omnicom (OPMG). Omnicom Group is a strategic holding company that has the industry's most diverse portfolio of more than 1,000 companies serving over 5,000 clients in more than 100 countries. Nelson has served in leadership roles with BBDO, TBWA, Ogilvy and Wunderman Thompson and worked on brands like Eli Lilly, Ford, Microsoft, P+G, SAP, Google, Citibank, etc. What You'll Discover in this Episode: The biggest fact makes for great leadership. What Nelson learned about giving and receiving feedback from his first mentor. Why it's vital for every leader to develop their own point of view. Surprising leaders and industries that can inspire and shape your point of view. A failure that accelerated his growth and job promotion. Resources: https://www.linkedin.com/in/nelson-freitas-b616a93/ (Nelson's LinkedIn Profile) https://omnicommediagroup.com/ (Omnicom) https://en.wikipedia.org/wiki/Serena_Williams (Serena Williams) https://en.wikipedia.org/wiki/Tom_Ford (Tom Ford) https://en.wikipedia.org/wiki/Mike_Amiri (Amiri) https://resources.kenblanchard.com/blanchard-leaderchat/developing-your-leadership-point-of- (Developing Your Leadership Point of View), Ken Blanchard https://www.ariannahuffington.com/the-sleep-revolution/ (The Sleep Revolution), Arianna Huffington Quotes: “Be good. Lead with purpose.“ ----- Connect with the Host, #1 bestselling author Ben Fanning https://www.benfanning.com/speaker/ (Speaking and Training inquires) https://followbenonyoutube.com (Subscribe to my Youtube channel) https://www.linkedin.com/in/benfanning/ (LinkedIn) https://www.instagram.com/benfanning1/ (Instagram) https://twitter.com/BenFanning1 (Twitter)
Jury trials under the False Claims Act (FCA) can produce very wild outcomes. In this episode, Captain Integrity Bob Wade breaks down what went down in the recent Eli Lilly/Astellas Pharma case. Hear why jury trials under the FCA are extremely rare, there are large jury verdicts, an effective compliance program can reduce or eliminate the risk of going to court, how big a return the government can receive, and how a mistake could be considered fraud. Learn more at CaptainIntegrity.com
In today's episode, Matthew Clemente talks about the product and engineering scaling challenges working in the biomedical industry. Key Takeaways: An overview of the Biomedical Industry Understanding the Biomedical regulatory overhead on the product roadmap Testing and regulatory issues. Acceleration and efficiencies in the development process. Understanding the team's role & risk management. Mission-driven drivers Connect with Matthew Clemente at https://www.linkedin.com/in/prspctvs About today's guest: Matthew Clemente currently serves as the Senior Vice President of Product & Development at Bigfoot Biomedical, responsible for an innovative, emerging portfolio of diabetes care services and technologies transforming existing care models. Matthew previously served as the Corporate Vice President of Delivery Systems Engineering at Novo Nordisk and as the Senior Director and Chief Technology Officer at Eli Lilly & Company, where he led the development of portfolios of connected drug delivery devices, applications, and algorithms that served as the foundation of both drug manufacturers and connected diabetes ecosystems. Before that, he was the Director of Advanced Drug Delivery Systems at Unilife Corporation. He built and managed an integrated engineering and science organization focused on mechanical, electromechanical, digital, and container closure systems for prefilled, preassembled, wearable drug delivery applications. Before Unilife, Matthew held various roles of increasing responsibility at multiple Johnson & Johnson companies. He primarily served in the new product development of insulin pumps at Animas Corporation for J&J's Diabetes Care Franchise. Matthew obtained a Bachelor of Science in Biomedical Engineering from the University of Miami and an MBA in Finance from Villanova University. ________ Thank you so much for checking out this episode of The Tech Trek and if you enjoyed this episode, please take a minute and leave a quick rating and review on the Apple podcast app! Want to learn more about us? Head over at https://www.elevano.com Have questions or want to cover specific topics with our future guests? Please message me at https://www.linkedin.com/in/amirbormand (Amir Bormand)
Dr. Timothy T. Baldwin is the Randall L. Tobias Distinguished Chair in Leadership and Professor of Management at the Indiana University Kelley School of Business. Professor Baldwin holds a Ph.D. in Organizational Behavior from Michigan State University and an MBA from MSU as well. He has published his research work in leading academic and professional outlets and has won several national research awards – including eight best-paper awards from the National Academy of Management. He has twice received the Richard A. Swanson Excellence in Research Award presented by the American Society for Training & Development (ASTD). He is the co-author of three books, Improving Transfer Systems In Organizations (Jossey Bass: 2003); Developing Management Skills: What Great Managers Know and Do (McGraw-Hill: 2012); and Organizational Behavior: Real Solutions to Real Challenges (McGraw-Hill: 2020). In his 35th year at Indiana University, he has frequently been recognized for teaching excellence. His background includes consulting with Cummins Engine, Eli Lilly, FedEx, Whirlpool, and various other organizations. Professor Baldwin was the Chair of the Dept. of Mgmt. & Entrepreneurship from 2014-2020, and currently serves on the Board of Directors of Cripe Architects & Engineers and World Arts, Inc.Professor Baldwin is married with one son, one dog, one cat, and his interests include coaching youth sports, golf, gardening, and a little amateur magic. Resources Mentioned in This EpisodePodcasts: Adam Grant & Tim FerrisTV Show: Magic for HumansTim Baldwin at Google ScholarOrganization: RingorangBook: The College ScamOnline Course: The New Manager's Toolkit "Just in time, just enough, just for me" - RosenbergA Quote From This Episode"Let's shrink the change. Let's get very targeted. Let's make it just for that audience and in their environment."About The International Leadership Association (ILA)The ILA was created in 1999 to bring together professionals interested in the study, practice, and teaching of leadership. Plan for ILA's 24th Global Conference online on October 6 & 7, 2022, and/or onsite in Washington, D.C., October 13-16, 2022. Register for the 24th Global Conference here!The Prometheus ProjectAbout The Prometheus ProjectFocus Series Experience - Immunity to Change workshopMy Approach to HostingThe views of my guests do not constitute "truth." Nor do they reflect my personal views in some instances. However, they are important views to be aware of. Nothing can replace your own research and exploration.Connect with Scott AllenWebsite
The investigation into the illegal promotion of the drug Zyprexa by the US justice department resulted in the largest sum for both a corporate whistleblower claim and the largest criminal fine ever imposed by the US upon a single company. On today's podcast we welcome Jim Gottstein, famous for subpoenaing and releasing the Zyprexa papers.The Zyprexa Papers Paperback - Jim GottsteinIf you are in a crisis or think you have an emergency, call your doctor or 911. If you're considering suicide, call 1-800-273-TALK to speak with a skilled trained counselor.RADICALLY GENUINE PODCASTRadically Genuine Podcast Website Twitter: Roger K. McFillin, Psy.D., ABPPInstagram @radgenpodTikTok @radgenpodRadGenPodcast@gmail.comADDITIONAL RESOURCES4:30 - Eli Lilly Said to Play Down Risk of Top Pill - The New York Times5:00 - Eli Lilly and Company Agrees to Pay $1.415 Billion to Resolve Allegations of Off-label Promotion of Zyprexa11:00 - Mad in America: Bad Science, Bad Medicine, and the Enduring Mistreatment of the Mentally Ill: Whitaker, Robert12:00 - Law Project for Psychiatric Rights20:00 - Olanzapine (Zyprexa) | NAMI: National Alliance on Mental Illness37:00 - The Psychiatric Drugging of Children & Elderly44:00 - PsychRights: Lucy Booth: Psychiatric "help" - The Doctor was Fooled or Complicit54:00 - Why is the FDA Funded in Part by the Companies It Regulates? - UConn Today.54:40 - Federal Register :: Revised Draft Guidance for Industry on Distributing Scientific and Medical Publications on Unapproved New Uses-Recommended Practices; Availability59:00 - A Strategic Approach to Mental Health System Change1:02:30 - California COVID misinformation bill targets doctors spreading false information
In Alzheimer's, three drug candidates capture most of the industry's attention these days, and for good reason. They're all in late-stage development and have the likes of Biogen, Eisai, Genentech and Eli Lilly backing them. But in this week's episode, we step away from the big three. The Alzheimer's Association found that there are 143 drugs in the pipeline. If fully enrolled, these trials would involve 50,575 people and more than 3.8 million participant weeks. We'll dive into these details and more tidbits from AA's report. And that's not all. As we gear up to publish our annual Fierce 15 report honoring biotechs with the most exciting technologies, we're also taking the time to look back at our 2012 class of Fierce 15. By now, several companies have fallen off the map, but many others were part of blockbuster deals or continue to plug away at their pipelines. We profile all of them, what they've been up to and what's coming next. To learn more about topics in this episode: Beyond headlines and amyloid, the Alzheimer's pipeline chugs along Where are they now? Tracking down 2012's Fierce 15 The Top Line is produced by senior multimedia producer Teresa Carey with managing editor Querida Anderson and senior editors Annalee Armstrong, Ben Adams, Conor Hale and Eric Sagonowsky. The sound engineer is Caleb Hodgson. The stories are by all our “Fierce” journalists. Like and subscribe wherever you listen to your podcasts.See omnystudio.com/listener for privacy information.
You've probably spent your entire life believing that you should do what you're good at. Surely, if you're a natural at something, then it's your life's calling, right? But what if you've been wrong all along? Gary Hobbs, electrical engineer turned entrepreneur, believes it's the challenges you face, doing what you love, and doing what you're GREAT at will drive your success. In this episode of the Hot Mess Hotline, you will hear how important it is to weigh the risks of doing what you're good at when you're feeling unfulfilled. Can you find freedom by facing challenges and being fulfilled by chasing your passion? Gary took a leap that changed the course of his career. Although initially he felt like he made a big Hot Mess, what he really uncovered was his passion, his calling, and more success than he could have ever dreamed of. Exploring the tension of leaving a successful business for the unknown was a leap of faith, but it's usually the biggest leaps that have largest rewards. Join Gary and myself as we talk all things risk, reward, failure, success, and overcoming challenges on this interview. You will laugh along side us, learn several lessons listed below, but most of all, you will be challenged to ask yourself if you're comfortable enough to step out from behind the ease of success to embrace the risk of facing challenges to uncover your greatest passions. Here are a few lessons that Gary learned the hard way so we don't have to : More focus equals more success Not all skills are transferable Just because you're good at something doesn't mean you should stick with it Success is more than just money If you can let go of what isn't your work to do, you'll see greater blessings Increased confidence comes from overcoming challenges Humility comes from understanding there are some external factors that could shut down your business or career Use your faith and spirituality to stay grounded Empathy is the ultimate leadership skill About Gary Hobbs Gary Hobbs is an entrepreneur and former corporate executive with extensive experience in real estate, technology, education, and healthcare. He started his career as an electrical design engineer and has successfully migrated through the corporate ranks of companies like AT&T, Eli Lilly, and Roche Diagnostics. As an engineer, project manager, business executive, developer, and entrepreneur he has led organizations of up to four hundred people and budget responsibilities spanning well over $100M. Currently, he is CEO for Black and White Investments, LLC. Gary founded BWI in 2005 as a development and construction management company. BWI's target market is urban development within Indiana and their primary focus is multi-family and mixed-use tax credit developments. About BWI BWI, LLC is a construction, real estate development, property management, consulting and electrical firm in the greater Indianapolis area that focuses on not only construction management of general, large development projects, but also niche, energy-efficient urban revitalization projects. BWI has extensive capabilities helping clients design, develop and manage their projects with a special emphasis in electrical and eco-friendly, sustainable development. Their development and construction services can be accomplished under a consultative or design-build basis. BWI, founded in 2005, is headquartered in Indianapolis, Indiana. Their number one aspiration is to bring hope to under-served urban communities via economic development that align with their Quality of Life aspirations and initiating in collaborative partnerships. Lead Kick Ass Meetings: Complimentary Resource Meetings are a really expensive use of your time. It only makes sense that they need to be more productive and valuable. Instead of running meetings that could have been an email, lead powerful meetings that have purpose, participation, and problem solving.
TRC Editor, Dr. Lori Dickerson, PharmD, FCCP talks with Joseph Saseen, PharmD, FCCP, FNLA, Associate Dean for Clinical Affairs, Professor, Department of Clinical Pharmacy and Professor, Department of Family Medicine from the Skaggs School of Pharmacy and Pharmaceutical Sciences at the University of Colorado Anschutz Medical Campus about managing statin intolerance. Listen in as they discuss how to evaluate statin-associated muscle pain...and review strategies to help patients take a statin successfully. You'll also hear practical advice from panelists on TRC's Editorial Advisory Board:Andrea Darby Stewart, MD, Associate Director, Family Medicine Residency at Honor HealthAnthony A. Donato, Jr., MD, MHPE, Associate Program Director, Internal Medicine from the Reading Health System, and Professor of Medicine at the Sidney Kimmel Medical College at Thomas Jefferson UniversitySteven E. Nissen, MD, MACC, the Chief Academic Officer at the Heart and Vascular Institute and the Lewis and Patricia Dickey Chair in Cardiovascular Medicine Professor of Medicine at the Cleveland Clinic Lerner School of Medicine at Case Western Reserve UniversityJoseph Scherger, MD, MPH, Family Physician, Primary Care 365, Eisenhower HealthCraig D. Williams, PharmD, FNLA, BCPS, Clinical Professor, Department of Pharmacy Practice at the Oregon Health and Science UniversityFor the purposes of disclosure, Dr. Steven Nissen reports a relevant financial relationship with AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Esperion, Medtronic, Novartis, Pfizer, Silence Therapeutics (grants/research support).The other speakers have nothing to disclose. All relevant financial relationships have been mitigated.Pharmacist's Letter offers CE credit for this podcast. Log in to your Pharmacist's Letter account and look for the title of this podcast in the list of available CE courses.If you're not yet a Pharmacist's Letter subscriber, find out more about our product offerings at trchealthcare.com. Follow or subscribe, rate, and review this show in your favorite podcast app. You can also reach out to provide feedback or make suggestions by emailing us at ContactUs@trchealthcare.com.
Enhanced Longevity and Health with Dr. Joseph Antoun Hello beautiful humans, thank you for listening and supporting the Thrive Forever Fit Show. It truly means the world to me that you take time out of your precious day to listen to me ramble and rant about things I found entertaining, engaging, and meaningful. SPONSOR: Elite Collagen ~ Visit: https://www.thriveforeverfit.com/store/ For Details.
Jeanie chats with the founder and CEO of Noetic Consultants, Nancie McDonnell Ruder. We chose to replay this episode because you'll quickly learn that Nancie and her team are so much more than marketing strategy and research and training. She takes such a personal and textured approach to her clients and to the world around her. Jeanie and Nancie dive into the ingredients of a good day, as well as a tough day. They share personal rituals and practices that help keep them on the course of their own evolution and growth and happy life.With over 20 years experience in marketing strategy, marketing training, branding and consumer research, Nancie loves building brands and helping people get better equipped to do so. She began her professional career with the Leo Burnett Company in Chicago, Illinois, where she served clients such as Procter & Gamble, Eli Lilly, The Gap, Lexmark Computers and Hoerchst Marion Rousseau. She launched Noetic Consulting in 2002 with the mission to “equip the people who build the brands using consumer research, brand strategy, training and other services and tools”. Through Noetic, Nancie has provided strategic guidance to clients large and small, including: AT&T, Discovery Channel, Georgetown University, McCann Worldgroup, Nike, Vail Resorts, Samsung Electronics, SC Johnson, Baywa Renewal energy and others. This is a very personal and practical conversation that you're sure to enjoy!(1:45) Jeanie shares how she met Nancie(4:36) Nancie's personal philosophy(8:25) Nancie describes her ideal day & routines (15:30) How to shift your energy(16:48) Noetic's Core Values(23:13) A proud moment from Nancie's 19 & 3/4 years in business(25:50) Nancie reflects on a unique client and learning experience from her past(28:20) Nancie & Jeanie discuss their support circles(37:45) What can we walk away with from this conversation? Connect with Nancie McDonnell Ruderhttps://www.linkedin.com/in/nancieatnoetic/ Subscribe: Warriors At Work Podcasts Website: https://jeaniecoomber.comFacebook: https://www.facebook.com/groups/986666321719033/Instagram: https://www.instagram.com/jeanie_coomber/Twitter: https://twitter.com/jeanie_coomber LinkedIn: https://www.linkedin.com/in/jeanie-coomber-90973b4/YouTube: https://www.youtube.com/channel/UCbMZ2HyNNyPoeCSqKClBC_w
The last two years have provided updated guidelines on management of chronic kidney disease in type 2 diabetes alongside new regulatory approvals of pharmacotherapies. In this episode we speak to Dr David Cherney about the implications of these updates and advancements. By completing this activity, you can qualify for 0.25 CME credits. To claim your credits, you must listen to the podcast and successfully pass the post-module assessment at https://diabetes.knowledgeintopractice.com, where you can find all past episodes of the podcast as well as other free CME resources. References available here Disclosures: Dr David Cherney declares the following financial relationships from the past 24 months: Honoraria: Boehringer Ingelheim-Lilly, Merck, AstraZeneca, Sanofi, Mitsubishi-Tanabe, Abbvie, Janssen, Bayer, Prometic, BMS, Maze, Gilead, CSL-Behring, Otsuka, Novartis, Youngene and Novo-Nordisk Grant/Research support: Boehringer Ingelheim-Lilly, Merck, Janssen, Sanofi, AstraZeneca, CSL-Behring, and Novo-Nordisk. Liberum IME staff, ACHL staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose. The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity. Funding: This independent educational activity is supported by an educational grant from Eli Lilly. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Eli Lilly has had no influence on the content of this education.
Episode #33 - Client Spotlight: How Tayla Mahmud Discovered Herself and Found Her Aligned Career I always say that navigating your career path in midlife requires mastery of both an inner (mindset and self-discovery) game and an outer (tactics and strategy) game. This concept is the foundation of the Career Rebel Academy and what helps my clients achieve the success and results they desire. Today on the podcast, CRA student Tayla Mahmud shares where she was before joining CRA, why she joined six months pregnant, and how being in the program has helped get her the clarity she needs to design a career and life she loves. In this episode of the Midlife Career Rebel Podcast, you'll discover… Tayla's experience in the Career Rebel Academy Where she was before she started the program How the mindset and discovery work gave her the clarity she needed The importance of community and how it helped her Why coaching and not trying to go it alone is so important How she was able to choose the right career path/job Advice for those considering the Career Rebel Academy Featured On the Show: Career Rebel Academy: https://bit.ly/3mZ7Mwm The Alchemist by Paulo Coelho: https://buff.ly/3cUzOkR Mindset by Carol Dweck: https://buff.ly/3Q2MCca About Our Guest: Tayla Mahmud is the Executive Vice President, Health Equity & Multicultural Strategy at M Booth Health. In her role, she leads and guides the agency's work on Health Equity and Multicultural Communications by counseling public affairs, social impact, and marketing communications clients on strategies to advance health equity, reach diverse communities, and demonstrate commitment to reducing disparities. Tayla is most passionate about advancing diversity, equity and inclusion in healthcare. Tayla has counseled health organizations on DE&I strategy and cross-cultural communications. She has worked with diverse patient populations to create inclusive programs to address care gaps. Tayla is also an active writer and speaker on the importance of addressing inequities in healthcare, communications, and business. Recognized by the Healthcare Businesswomen's Association, Tayla built her career leading agency teams to develop integrated health campaigns across therapeutic areas such as diabetes, immunology, neurology, pain, women's health and vaccines. This work has reached diverse stakeholders including patients, advocacy groups, healthcare professionals, payers and healthcare executives. She has served as a strategic partner to many top pharma clients including AbbVie, Biogen, Eli Lilly, Merck and Pfizer. Email me if you have a question or ideas for the podcast at email@example.com. Check out my FREE monthly roundtable called The Boardroom, where we discuss the current issues impacting high-achieving professional women in midlife: https://buff.ly/3ljiYls Get access to my FREE training 10-Minute Career Jumpstart. Three videos to help you clarify your current career challenges, master a proven system to get the career and life you want, and learn why now is the best time to take action: https://bit.ly/10MinCareerJumpstart Rate, Review & Follow on Apple Podcasts "I'm loving the Midlife Career Rebel Podcast!" If that sounds like you, help us support more people like you to create a career and life they love. After all, the Midlife Career Rebel Podcast would not be possible without you. Click on the link below to subscribe, give us a five star rating, and leave a review on Apple Podcasts and Spotify. Apple Podcast Spotify Thanks for listening, Carol Be sure to follow me: Website: https://www.carolparkerwalsh.com/podcast LinkedIn: https://linkedin.com/in/parkerwalsh Instagram: https://instagram.com/drcarolparkerwalsh Twitter: https://twitter.com/drcpwalsh Facebook: https://facebook.com/DrCarolParkerWalsh YouTube: https://youtube.com/carolparkerwalsh
R. Ethan Braden serves as Executive Vice President and the chief marketing and communications officer at Purdue University and Purdue Global. Ranked as one of the Top Ten Most Innovative Schools in America by US News and World Report for four consecutive years, Ethan leads the system in the persistent pursuit of the next giant leap by passionately positioning, promoting, and protecting the Purdue brand and portfolio worldwide.In October 2021, Fast Company Magazine selected Purdue University as one of its inaugural “Brands That Matter,” a list honoring companies and organizations that authentically communicate their mission and ideals and give people compelling reasons to care about them according to Fast Company editors. The only university and the only Indiana entity named a Brand That Matters, Purdue was selected alongside Nike, 3M, McDonald's, Ford, Yeti, and other large multinational conglomerates, small companies, and nonprofits.In 2020, the American Marketing Association recognized Ethan as ‘Marketer of the Year,' and Purdue University's central marketing and communications team as ‘Team of the Year,' both for higher education.He has appeared in Fast Company magazine, the Washington Post, AdAge, The Hechinger Report, and The Morning Brew. Ethan has spoken at Google Marketing Live and Salesforce's Dreamforce, as well as appeared on numerous podcasts related to brand management, marketing, and higher education. Ethan teaches personal branding to student-athletes in Purdue University's Optimizing Personal Brand and Image class, an innovative partnership between Purdue's School of Management and Purdue Athletics prompted by NIL.Previous to Purdue, Ethan worked for Eli Lilly & Company for over a decade, where he served in a variety of senior marketing and sales leadership roles in the U.S. and globally, building, launching, and managing some of Lilly's and the pharmaceutical industry's most successful and life-changing, billion-dollar brands.Ethan earned his MBA from the University of Notre Dame and his bachelor's degree from Willamette University (Salem, Oregon). Ethan lives in West Lafayette, Indiana, with his wife, Betsy, their son, Benjamin, and their daughter, Margaret.Two Quotes From This Episode"When we read together, and we consume together, it creates common knowledge. And it creates a common language...there's a common language that pervades the community of employees as a result of referring to the same texts.""The transition that we've made in our industry over time went from marketing, to brand, to now storytelling. And I don't care what you're in, great stories beat great spreadsheets."Resources Mentioned in This EpisodeThe episode title is taken from the book Long Life Learning: Preparing for Jobs that Don't Even Exist YetLinks to resources are located in the transcript!About The International Leadership Association (ILA)The ILA was created in 1999 to bring together professionals interested in the study, practice, and teaching of leadership. Plan for ILA's 24th Global Conference online on October 6 & 7, 2022, and/or onsite in Washington, D.C., October 13-16, 2022. Register for the 24th Global Conference here!My Approach to HostingThe views of my guests do not constitute "truth." Nor do they reflect my personal views in some instances. However, they are important views to be aware of. Nothing can replace your own research and exploration.Connect with Scott AllenWebsite
Let's talk about Eli Lilly, Indiana, and more to come.... --- Send in a voice message: https://anchor.fm/beau-of-the-fifth-column/message Support this podcast: https://anchor.fm/beau-of-the-fifth-column/support
Lauren Thomas, Retail Reporter at CNBC, joins Marketing Matters to discuss Marketing News of the week including Everlane's anti-inflation sale, Layoffs at startups such as Warby Parker and Allbirds, Large Indiana employers Eli Lilly and Cummins speak out about the state's new restrictive abortion law, and more!
Woman Empowerment, Lifestyle and how to become a Lady Boss. Hey Beauties, on this week's podcast, I have the pleasure of interviewing none other than Allergan Aesthetics Senior Vice President of US Brands, Edrice Simmons. Simmons started her career at Eli Lily; an Internation pharmaceutical company worth $24 billion. Simmons has received countless awards, multiple performance-based promotions, and exceptional contributions throughout her time at Eli Lilly. Simmons then moved on to AbbVie as a Senior Marketing Director of Immunology where 5 years later she became senior VP of US Brands. We take a deep dive into how Edrice got to where she is today and discuss more on lifestyles, habits, and how we can better ourselves to become the best version of ourselves we can be. Listen in to find out more about Edrice and how to be a boss babe. Click Here to check out my Instagram! Click Here to check out my skincare products! Click Here to listen to more podcasts!
New research from multiple studies – yet to be published – was highlighted at the Alzheimer's Association International Conference in San Diego, August. This hour on Where We Live, we discuss studies that show high blood pressure during pregnancy; consumption of highly processed foods; and the loss of smell and taste are all predictors of cognitive decline later on. We hear from an Alzheimer's patient and his caregiver wife about life before and after joining an Eli Lilly clinical trial. And later, we hear about new research on how experiencing discrimination and racism increases the risk of memory loss. According to the Alzheimer's Association, there are 6 million Americans living with Alzheimer's disease. In Connecticut, that number is 80,000. Nationally, two-thirds of women have Alzheimer's and two-thirds of women are caregivers for someone who has the disease. GUESTS: Sandi and George Carlino: George has early stage Alzheimer's and is in an Eli Lilly clinical trial in New Haven. Dr. Amy Sanders: Medical Director of the Hartford HealthCare Memory Care Center, and a Medical Scientific Advisory Council member at the Alzheimer's Association, Connecticut Chapter. Dr. Carl Hill: Chief Diversity, Equity and Inclusion Officer, Alzheimer's Association. Support the show: http://wnpr.org/donateSee omnystudio.com/listener for privacy information.
Crain's commercial real estate reporter Danny Ecker talks with host Amy Guth about how the city has added a twist to its approach to further promote development in under-resourced areas. Plus: Senate passes Democrats' landmark tax, climate, drugs bill; all eyes on Chicago as it launches the nation's biggest guaranteed-income programs; WeWork offices now just as full as they were before the pandemic; and Eli Lilly says Indiana abortion law will force hiring out-of-state.
While you were (completely justifiably) celebrating the passage of the Inflation Reduction Act, the racists of CPAC were telling us who they are - literally announcing "We are all domestic terrorists." And Trump was simply promising a personal takeover of the National Guard, detention camps, and a military dictatorship. We also saw three retiring Republican Senators who could've capped the price of Insulin fail to muster the 1% courage required to do so. Also in this episode: Pete Rose reappears and tips off three separate baseball controversies in one day, the L.A. Times butchers the details of the career of the late Vin Scully, Marco Rubio uses the most modern obvious Antisemitic dog whistle, and I celebrate the 17th anniversary of the day I nearly had to call the police because yet another soon-to-be-ex-president of MSNBC chased me around the studios, threatening to kill me. On that happy note: enjoy our second week on Countdown!See omnystudio.com/listener for privacy information.
Britney Spears v. K-Fed, Anne Heche takes out a house, Kim K & Pete Davidson split, Terrell Owens almost died, two men outed 110 years after dying on the Titanic, AIDS patient zero, and Maz recaps being in the Mall of America lockdown last Thursday.Drew and Marc are refrigerator brothers.Drew has completed 176,000 sit ups.Sports Weekend: Lou Whitaker Retirement Day at Comerica Park was classy, well done and hotter than hell. The "Jacob deGrom bros" beat the crap out of a Atlanta Braves fan. Pete Rose doesn't want to talk about nailing 14-year-olds 55 years ago, babe. Terrell Owens is really stretching out his 'Karen' encounter as he now claims he could have been killed. Men are dominating the professional female disc golf. Alberto Nonino's massive wang was on full display during a decathlon. Gen Z loves MSU athletics.Detroit sure did have a lot of gun violence this weekend.WDIV Local 4 Weather reporters report: Kim Adams is back! Andrew Humphrey is doing weather reports from his car just like your smartphone. Ben Bailey is still MIA.An LA police chase ends with a surrender to nobody and one very confused criminal.Anne Heche was hospitalized after crashing all over a Los Angeles neighborhood. She took out a garage and then tried to drive through a home. A GoFundMe has been set up by the homeowner. Alec Baldwin makes it all about him while plugging his old movies.Tom Mazawey was locked down at the Mall of America after shots rang out. We check in with him after his vacation. He also might need to start a GoFundMe after being suffering a great loss in the Detroit Tigers' Champions Club today. John Leguizamo is angry that a movie is being made about Fidel Castro even though he knows nothing about it. He's also not happy James Franco will play Fidel Castro because he's not Hispanic.Britney Spears Watch: K-Fed breaks his silence about how Sean Preston and Jayden James are embarrassed by their mom. Sam Asghari slaps back now that it's his "gravy train". Britney Spears goes ballistic. Jamie Spears wants to un-seal Britney's medical records to prove to everybody how crazy she is.Tyler Perry loves Meghan Markle for some reason that no one can figure out. Grab your EXCLUSIVE NordVPN Deal by going to nordvpn.com/dams or use the code dams to get a HUGE Discount off your NordVPN Plan + 1 additional month for free + a bonus gift! It's completely risk free with Nord's 30-day money-back guarantee!Kim Kardashian and Pete Davidson split. His tattoos didn't age too well.Alex Jones owes $50M to the parents of Sandy Hook victims with multiple trials left to go. He also saved a man's life after the verdict.The American Massage Therapy Association conference is in Cleveland this year... just like Deshaun Watson. Stephen Ross believes he's being punished for Watson's misdeeds.Mitch Albom has a pretty good take on Brittney Griner.Anne Heche's family life was pretty bad.Patient Zero, Gaëtan Dugas, is apparently not Patient Zero anymore.The WaPo outs two men that died 110 years ago on the Titanic.Dane Cook's game nights were filled with underage hotties.Indiana is the first state to pass abortion legislation following the Roe v. Wade reversal. Eli Lilly is going to pack up and take their business elsewhere.The Inflation Reduction Act has been passed so everything will be cheap soon.Texas is sending their migrants to New York and Washington DC.Social media is dumb, but we're on Facebook, Instagram and Twitter (Drew and Mike Show, Marc Fellhauer, Trudi Daniels and BranDon).
Hosts Rebeca Ibarra and Dave Smith are updating the news, all day, every weekday. Welcome! Arbery's killers receive federal sentences [Share] Cox buys Axios for $525 million [Share] Pharmaceutical giant Eli Lilly weighs in on Indiana abortion law [Share] AR-15s in NC schools [Share] Olivia Newton-John has died [Share] We're updating the news Coming up: stop working so hard Senate GOP blocks insulin cap [Share] Muslim community targeted in 4 killings [Share] TX Gov Greg Abbott appoints indicted officer to commission [Share] Qantas asks senior execs to be bag handlers [Share] Historian David McCullough dies at 89 [Share] Can working less help us be more productive? [Share] Talk to you soon!
Morse code transcription: vvv vvv Horniman Museum to return 72 artefacts to Nigeria Flash flooding swamps Californias Death Valley The newborns fighting for survival in Afghanistan What the Alex Jones trial means for the future of conspiracy culture Multiple people injured in Cincinnati shooting GMA ABC News Republicans block cap on insulin costs for many Americans from Democratic deal Biden stands with Muslims after horrific killings in New Mexico I cant do it again Can Appalachia blunt the devastating impacts of more flooding, climate change Brazilian Jiu Jitsu great Leandro Lo shot in head in Sao Paulo club Israel Gaza Hopes as Gaza ceasefire comes into effect Race to rescue trapped miners in Mexico Climate change US takes step closer to passing historic bill Ukraine war Four more grain ships leave Ukraine as hopes grow for export stability Five Decades in the Making Why It Took Congress So Long to Act on Climate Heres how the Inflation Reduction Acts rebates and tax credits for heat pumps and solar can lower your energy bill Sanya Covid lockdown strands tourists on Chinas Hawaii U.S. Senate approves bill to fight climate change, cut drug costs in win for Biden Pharma company Eli Lilly expanding outside of Indiana over states abortion law Israel Gaza Talks under way to broker ceasefire in Gaza France whale Lost mammal stuck in River Seine to get vitamin boost
Morse code transcription: vvv vvv Gambling disorder It took me to save Peter Shilton In wake of floods, typical barbs at Kentucky political event Albuquerque police, FBI investigating possible link between four murdered Muslim men Senate Democrats Close In on Passing Climate and Tax Bill Race to rescue trapped miners in Mexico Deadly lightning strike kills LA resident Biden tests negative for Covid after rebound case doctor Flooding in Death Valley strands drivers, hotel guests As tensions rise, Taiwan says China military drills appear to simulate attack Israel Gaza Palestinian civilians and militants killed amid flare up Taiwan US hits out at irresponsible China amid attack rehearsal claims Eli Lilly to seek employment growth outside of Indiana after abortion ban France whale Lost mammal stuck in River Seine to get vitamin boost Ukraine war Four more grain ships leave Ukraine as hopes grow for export stability Uganda LGBT rights Government shuts down key advocacy group Alex Jones to pay Sandy Hook parents nearly 50M in total USA TODAY USA TODAY Ohio shooter who allegedly killed 4 has been arrested following manhunt, police say Sanya Covid lockdown strands tourists on Chinas Hawaii Israeli Airstrikes Hit Gaza for 2nd Day Militants Respond With Rockets Archie Battersbee fought until the end, says mum after son dies
Morse code transcription: vvv vvv Zaporizhzhia Russian strikes cause damage at nuclear plant Breonna Taylor Raid Puts Focus on Officers Who Lie for Search Warrants Croatia bus crash Twelve Polish pilgrims killed and 31 injured Race for Washingtons 3rd District second slot narrows as more ballots are counted Judith Durham Former Seekers lead singer dies aged 79 Biden tests negative for Covid after rebound case doctor Senate on track to take key vote Saturday to advance Democrats sweeping health care and climate bill Israel Gaza Palestinian civilians and militants killed amid flare up 3 Muslim men in Albuquerque were murdered. Police are investigating possible ties to same killer Large Indiana employers Eli Lilly and Cummins speak out about the states new restrictive abortion law Lightning strike causes major fire at Cuban fuel depot Windsor Hills crash victim, son, and fianc were headed to pregnancy checkup Alex Jones must pay extra 45m for hoax claims Biden Tests Negative for Coronavirus but Will Keep Isolating Taiwan US hits out at irresponsible China amid attack rehearsal claims 4 dead at multiple crime scenes in Ohio town. Police are searching for a man who is likely armed and dangerous Flash flood in Death Valley strands about 1,000 people in national park A jury finds Infowars conspiracy theorist Alex Jones should pay 45.2 million in punitive damages to the parents of a Sandy Hook shooting victim Archie Battersbee fought until the end, says mum after son dies Rishi Sunak No hope of election win if inflation sticks
It would be easy to say that Mike Mooney's career has been going in circles for more than 25 years in the high-speed world of professional motorsports. An award-winning executive, Mike built and protected the reputations of global brands such as Mercedes-Benz, 3M, NASCAR, Sunoco, Tylenol, Walmart, Sprint, Kellogg's, and Eli Lilly. Having worked with championship drivers and teams for decades, Mike saw the power and results of continuous improvement, mindset, and peak performance. With a passion for personal empowerment and results, Mike left a high-visibility and high-performing career to share his experiences and lessons as a professional speaker to help organizations and leaders find people-centered speed. Mike speaks, coaches, and consults with people who recognize that shifting is the new norm. He guides his audiences to proactively identify where, when, and how to shift in order to stay on track and in a position to win! His breakthrough book, Reputation Shift – Lessons from Pit Road to the Boardroom, is a toolbox with ready-to-use personal branding strategies for people who want to create greater personal and professional opportunities in their lives. This show is sponsored by Leopard Solutions Legal Intelligence Suite of products, Firmscape, and Leopard BI. Push ahead of the pack with the power of Leopard. For a free demo, visit this link: https://www.leopardsolutions.com/index.php/request-a-demo/ Link: Website: https://www.mikemooney.com/ LinkedIn: https://www.linkedin.com/in/mike-mooney-0a242b4/ YouTube: https://www.youtube.com/channel/UCV_pB--cym8DqyY0RvEYEfQ